Search

HOPE Act Final Regulatory Impact Analysis

The Health Resources and Services Administration (HRSA) has published the final Regulatory Impact Analysis (RIA) for the HOPE Act. This document details the anticipated costs and benefits associated with the implementation of the HOPE Act.

HRSA Announces 340B Rebate Model Pilot Program Application Process

The HRSA announced the application process for a voluntary 340B Rebate Model Pilot Program for qualifying drug manufacturers. The agency is also requesting public comment on the program's structure and application process, with a deadline of September 8, 2025.

HRSA Document HRSA-2026-0001-0001

The Health Resources and Services Administration (HRSA) has issued a new government document, identified as HRSA-2026-0001-0001. This notice serves as an informational update for healthcare providers and public health authorities within the United States.

HRSA Notice 2026-03838

The Health Resources and Services Administration (HRSA) has issued Notice 2026-03838. This notice provides general information and updates relevant to healthcare providers and public health authorities. Specific details regarding the content of the notice are available via the provided URL.

HRSA Lowers Out-of-Pocket Medication Costs at Health Centers

The Health Resources and Services Administration (HRSA) has issued updated award terms requiring HRSA-funded health centers to provide insulin and injectable epinephrine to low-income patients at or below the price paid by the center through the 340B Drug Pricing Program. This action aims to lower out-of-pocket costs for life-saving medications nationwide.

HRSA Health Centers Served Record 32.4 Million Patients in 2024

The Health Resources and Services Administration (HRSA) announced that HRSA-funded health centers served a record 32.4 million patients in 2024. The data highlights quality improvements and recognizes nearly 1,000 health centers with Community Health Quality Recognition badges.